 Connection
Jill Slansky to Cancer Vaccines
This is a "connection" page, showing publications Jill Slansky has written about Cancer Vaccines.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
3.124 |
|
|
|
-
Buhrman JD, Jordan KR, Munson DJ, Moore BL, Kappler JW, Slansky JE. Improving antigenic peptide vaccines for cancer immunotherapy using a dominant tumor-specific T cell receptor. J Biol Chem. 2013 Nov 15; 288(46):33213-25.
Score: 0.428
-
Buhrman JD, Slansky JE. Improving T cell responses to modified peptides in tumor vaccines. Immunol Res. 2013 Mar; 55(1-3):34-47.
Score: 0.411
-
Buhrman JD, Jordan KR, U'ren L, Sprague J, Kemmler CB, Slansky JE. Augmenting antitumor T-cell responses to mimotope vaccination by boosting with native tumor antigens. Cancer Res. 2013 Jan 01; 73(1):74-85.
Score: 0.403
-
Jordan KR, Buhrman JD, Sprague J, Moore BL, Gao D, Kappler JW, Slansky JE. TCR hypervariable regions expressed by T cells that respond to effective tumor vaccines. Cancer Immunol Immunother. 2012 Oct; 61(10):1627-38.
Score: 0.383
-
Kemmler CB, Clambey ET, Kedl RM, Slansky JE. Elevated tumor-associated antigen expression suppresses variant peptide vaccine responses. J Immunol. 2011 Nov 01; 187(9):4431-9.
Score: 0.372
-
Jordan KR, McMahan RH, Kemmler CB, Kappler JW, Slansky JE. Peptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigens. Proc Natl Acad Sci U S A. 2010 Mar 09; 107(10):4652-7.
Score: 0.331
-
Jordan KR, McMahan RH, Oh JZ, Pipeling MR, Pardoll DM, Kedl RM, Kappler JW, Slansky JE. Baculovirus-infected insect cells expressing peptide-MHC complexes elicit protective antitumor immunity. J Immunol. 2008 Jan 01; 180(1):188-97.
Score: 0.287
-
McMahan RH, McWilliams JA, Jordan KR, Dow SW, Wilson DB, Slansky JE. Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines. J Clin Invest. 2006 Sep; 116(9):2543-51.
Score: 0.261
-
Yoshimura K, Laird LS, Chia CY, Meckel KF, Slansky JE, Thompson JM, Jain A, Pardoll DM, Schulick RD. Live attenuated Listeria monocytogenes effectively treats hepatic colorectal cancer metastases and is strongly enhanced by depletion of regulatory T cells. Cancer Res. 2007 Oct 15; 67(20):10058-66.
Score: 0.071
-
Yoshimura K, Jain A, Allen HE, Laird LS, Chia CY, Ravi S, Brockstedt DG, Giedlin MA, Bahjat KS, Leong ML, Slansky JE, Cook DN, Dubensky TW, Pardoll DM, Schulick RD. Selective targeting of antitumor immune responses with engineered live-attenuated Listeria monocytogenes. Cancer Res. 2006 Jan 15; 66(2):1096-104.
Score: 0.063
-
Jain A, Slansky JE, Matey LC, Allen HE, Pardoll DM, Schulick RD. Synergistic effect of a granulocyte-macrophage colony-stimulating factor-transduced tumor vaccine and systemic interleukin-2 in the treatment of murine colorectal cancer hepatic metastases. Ann Surg Oncol. 2003 Aug; 10(7):810-20.
Score: 0.053
-
Wei P, Jordan KR, Buhrman JD, Lei J, Deng H, Marrack P, Dai S, Kappler JW, Slansky JE, Yin L. Structures suggest an approach for converting weak self-peptide tumor antigens into superagonists for CD8 T cells in cancer. Proc Natl Acad Sci U S A. 2021 06 08; 118(23).
Score: 0.046
-
McWilliams JA, McGurran SM, Dow SW, Slansky JE, Kedl RM. A modified tyrosinase-related protein 2 epitope generates high-affinity tumor-specific T cells but does not mediate therapeutic efficacy in an intradermal tumor model. J Immunol. 2006 Jul 01; 177(1):155-61.
Score: 0.016
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|